Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial

Auteurs

M. Ignatiadis, S. Litière, F. Rothe, S. Riethdorf, C. Proudhon, T. Fehm, K. Aalders, H. Forstbauer, P.A. Fasching, E. Brain, P. Vuylsteke, E. Guardiola, R. Lorenz, K. Pantel, K. Tryfonidis, W. Janni, M. Piccart, C. Sotiriou, B. Rack, J.-Y. Pierga